Big Pharma ramping up China R&D ops

Drug discovery and research activities have traditionally focused on diseases common in the U.S. and Europe. That is, after all, where the money is. But as Reuters expounds on in an analysis out today, China is grabbing an increasing share of the global R&D budget, with investigators launching a slew of new studies to help understand how to treat the country's huge population and tap into one of the fastest growing pharma markets on the planet. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."